• Este endereço de email está protegido contra piratas. Necessita ativar o JavaScript para o visualizar.

Artigos Científicos

sexta-feira, 01 dezembro 2017 14:15

A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults

Rate this item
(0 votes)

Carolyn Sikes1, Jeffrey G. Stark2, Russ McMahen1, Dorothy Engelking1

Neos Therapeutics Inc., Grand Prairie, TX, USA
Worldwide Clinical Trials, Austin, TX, USA

Journal of Attention Disorders: SAGE Journals

December 1, 2017


Objective: The purpose of this study was to compare the pharmacokinetics of a new extended-release amphetamine oral suspension (AMP XR-OS) with a standard extended-release mixed amphetamine salts product, Adderall XR®.

Method: In this single-dose, open-label, randomized, two-period, two-treatment crossover study, 42 healthy adult volunteers received 15 mL of AMP XR-OS in one period and a 30 mg Adderall XR capsule in another period (both containing 18.8 mg of amphetamine base) under fasted conditions. Blood samples were analyzed for d- and l-amphetamine concentrations, and pharmacokinetic parameters Cmax, AUC0-5, AUC5-last, and AUCinf were calculated to determine bioequivalence. Safety was monitored throughout the study.

Results: The 90% confidence intervals (CIs) for the log-transformed Cmax, AUC0-5, AUC5-last, and AUCinf fell within the accepted 80% to 125% range for establishing bioequivalence for d- and l-amphetamine. The most common adverse events were nausea and decreased appetite.

Conclusion: AMP XR-OS is bioequivalent to Adderall XR in healthy adult participants.

Ver artigo completo...

A Direção da SPDA - Sociedade Portuguesa de Défice de Atenção

Read 175 times Last modified on sábado, 18 abril 2020 11:03
© 2020 SPDA - Sociedade Portuguesa de Défice de Atenção. All Rights Reserved. Design by BID-lab